S&P 500 7,609.78 +0.13% NASDAQ 27,093.90 +0.03% DOW 51,307.79 +0.45% R2K 2,931.96 +0.90% VIX 16.10 +2.09%
Next Bullish Trade
LLY Eli Lilly and Company NYQ
$1,064.15 -18.05 (-1.67%)
Extended · +1.02σ Grade C
+ Compare Set alert Open in Sniper

Price chart

Overlay: Click earnings ▲ markers for day-move details

Loading 1Y daily…

Financial overlay · last 12 quarters

QuarterRevenue Net incomeOp income FCFNet margin Op margin
2026-03-31 $19.8B $7.4B $9.8B $2.8B 37.4% 49.4%
2025-12-31 $19.3B $6.6B $9.0B $0.3B 34.4% 46.6%
2025-09-30 $17.6B $5.6B $8.4B $6.0B 31.7% 47.6%
2025-06-30 $15.6B $5.7B $7.0B $1.3B 36.4% 45.1%
2025-03-31 $12.7B $2.8B $5.3B $-1.6B 21.7% 41.7%
2024-12-31 $nanB $nanB $nanB $nanB nan% nan%
2024-09-30 $nanB $nanB $nanB $nanB nan% nan%

Earnings replay · last 20 reports

DateEPS actual EPS estSurprise
2026-04-30 8.55 6.79 +25.9%
2026-02-04 7.54 6.91 +9.1%
2025-10-30 7.02 5.89 +19.1%
2025-08-07 6.29 5.50 +14.5%
2025-05-01 3.06 4.11 -25.6%
2025-02-06 4.88 5.01 -2.6%
2024-10-30 1.18 1.47 -19.5%
2024-08-08 3.92 2.77 +41.7%
2024-04-30 2.58 2.49 +3.7%
2024-02-06 2.49 2.37 +5.1%
2023-11-02 0.10 -0.12 +181.5%
2023-08-08 2.11 1.99 +5.9%
2023-04-27 1.62 1.73 -6.3%
2023-02-02 2.09 1.83 +14.1%
2022-11-01 1.98 1.94 +2.1%
2022-08-04 1.25 1.70 -26.3%
2022-04-28 2.62 2.29 +14.4%
2022-02-03 2.49 2.51 -0.7%
2021-10-26 1.94 1.96 -1.2%
2021-08-03 1.87 1.89 -1.0%

Earnings markers are overlaid on the price chart above. Transcript summaries require PERPLEXITY_API_KEY (deferred to a follow-up).

Peer comparison · Healthcare

Ticker ⇅ Mkt cap ⇅ P/E ⇅ Fwd P/E ⇅ P/S ⇅ EV/EBITDA ⇅ P/B ⇅ Gross M ⇅ Rev gr ⇅ EPS gr ⇅ FCF yld ⇅
LLY ★ $949B 37.7 23.9 13.1 27.3 30.5 82.8% 55.5% 169.9% 0.96%
UNH $343B 28.5 18.1 0.8 18.5 3.5 18.8% 2.0% 0.7% 5.15%
JNJ $537B 25.8 17.5 5.6 16.6 6.6 68.0% 9.9% -52.9% 2.33%
MRK $286B 32.6 12.1 4.3 11.2 6.2 76.7% 4.9% — 4.92%
ABBV $381B 105.1 13.3 6.1 14.8 -57.2 72.0% 12.4% -46.2% 5.47%
PFE $146B 19.5 9.0 2.3 7.8 1.6 74.8% 5.4% -10.1% 8.50%
TMO $179B 26.5 17.7 4.0 19.4 3.4 40.9% 6.2% 11.3% 3.08%
ABT $151B 24.4 14.3 3.4 15.2 2.9 56.5% 7.8% -19.7% 4.19%

Auto-seeded from sector. Click any ticker to switch.

Ownership

Top institutional holders

Top-10 concentration: 43.16%

HolderShares% out
Lilly Endowment, Inc 91,896,978 9.76%
Blackrock Inc. 66,380,842 7.05%
Vanguard Capital Management LLC 53,361,774 5.67%
PNC Financial Services Group, Inc. 51,328,908 5.45%
State Street Corporation 35,610,002 3.78%
FMR, LLC 26,341,031 2.80%
Capital Research Global Investors 24,632,647 2.62%
Vanguard Portfolio Management LLC 20,977,027 2.23%
Geode Capital Management, LLC 20,191,864 2.14%
Capital World Investors 15,621,813 1.66%

Insider activity · 90d

No insider trades for LLY in last 90d.

Analyst estimates

yfinance
Low
$850.0
Mean
$1215.1034
High
$1500.0
Analysts
29

Consensus: buy (mean 1.74194). Distribution requires FINNHUB_API_KEY.

SEC filings

FormFiled DescriptionAction
8-K 2026-05-20 8-K view ·
4 2026-05-19 FORM 4 view ·
4 2026-05-19 FORM 4 view ·
4 2026-05-19 FORM 4 view ·
4 2026-05-19 FORM 4 view ·
8-K 2026-05-07 8-K view ·
4 2026-05-07 Insider transaction (Form 4) view ·
10-Q 2026-04-30 10-Q view ·
8-K 2026-04-30 8-K view ·
4 2026-04-21 FORM 4 view ·
4 2026-04-21 FORM 4 view ·
4 2026-04-21 FORM 4 view ·
4 2026-04-21 FORM 4 view ·
DEF 14A 2026-03-20 DEF 14A view ·
4 2026-03-17 FORM 4 view ·
4 2026-03-17 FORM 4 view ·
4 2026-03-17 FORM 4 view ·
4 2026-03-17 FORM 4 view ·
4 2026-02-19 FORM 4 view ·
4 2026-02-18 FORM 4 view ·
4 2026-02-18 FORM 4 view ·
4 2026-02-18 FORM 4 view ·
4 2026-02-18 FORM 4 view ·
4 2026-02-18 FORM 4 view ·
4 2026-02-18 FORM 4 view ·
4 2026-02-18 FORM 4 view ·
4 2026-02-18 FORM 4 view ·
10-K 2026-02-12 10-K view ·
4 2026-02-11 FORM 4 view ·
4 2026-02-11 FORM 4 view ·
4 2026-02-11 FORM 4 view ·
4 2026-02-11 FORM 4 view ·
4 2026-02-11 FORM 4 view ·
4 2026-02-11 FORM 4 view ·
4 2026-02-11 FORM 4 view ·
4 2026-02-11 FORM 4 view ·
4 2026-02-11 FORM 4 view ·
4 2026-02-11 FORM 4 view ·
4 2026-02-11 FORM 4 view ·
4 2026-02-11 FORM 4 view ·
4 2026-02-11 FORM 4 view ·
8-K 2026-02-04 8-K view ·
4 2026-02-03 FORM 4 view ·
4 2026-02-03 FORM 4 view ·
4 2026-02-03 FORM 4 view ·
4 2026-02-03 FORM 4 view ·
4 2026-02-03 FORM 4 view ·
4 2026-02-03 FORM 4 view ·
4 2026-02-03 FORM 4 view ·
4 2026-02-03 FORM 4 view ·
4 2026-02-03 FORM 4 view ·
4 2026-01-21 FORM 4 view ·
4 2026-01-21 FORM 4 view ·
4 2026-01-21 FORM 4 view ·
4 2026-01-21 FORM 4 view ·
4 2026-01-08 Insider transaction (Form 4) view ·
4 2026-01-06 Insider transaction (Form 4) view ·
4 2025-12-30 Insider transaction (Form 4) view ·
4 2025-12-29 Insider transaction (Form 4) view ·
4 2025-12-29 Insider transaction (Form 4) view ·

About

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for …